Description

AxoGen Is Expanding Beyond Extremities—How OMF &d Head-and-Neck Training Could Unlock New Demand!

AxoGen, Inc.’s recent financial results for the third quarter of 2025 reveal a blend of robust revenue growth and strategic positioning within the nerve repair market. The company reported a significant 23.5% increase in quarterly sales year-over-year, amounting to $60.1 million. This growth is attributed to the expanded adoption of their nerve repair solutions across various target markets, including extremities, oral maxillofacial (OMF), and breast procedures. The Avance Nerve Graft remains a pivotal component driving this revenue increase, complemented by other products within their nerve repair portfolio. The company’s gross margin showed an improvement over the previous year, rising to 76.6%, driven by reduced inventory write-offs and lower shipping costs. However, AxoGen did face increased product costs, which the company anticipates will decrease over time as economies of scale are achieved.